Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

New England Journal of Medicine - Tập 344 Số 14 - Trang 1031-1037 - 2001
Brian J. Druker1, Moshe Talpaz2, Debra Resta3, Bin Peng4, Elisabeth Buchdunger4, J. Ford4, Nicholas Lydon4, Hagop M. Kantarjian5, Renaud Capdeville4, Sayuri Ohno-Jones1, Charles L. Sawyers6
1Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, University of Texas M.D. Anderson Cancer Center, Houston
2Departments of Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston
3Department of Oncology Clinical Research, Novartis Pharmaceuticals, East Hanover, N.J.
4Basel, Switzerland
5Leukemia, University of Texas M. D. Anderson Cancer Center, Houston
6Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199907153410306

10.1056/NEJM199904293401706

Silver RT, 1999, Blood, 94, 1517

Nowell PC, 1960, Science, 132, 1497

10.1038/243290a0

10.1126/science.2406902

10.1073/pnas.87.17.6649

10.1038/344251a0

10.1126/science.2408149

10.1172/JCI9083

10.1038/nm0596-561

Deininger MW, 1997, Blood, 90, 3691, 10.1182/blood.V90.9.3691

10.1006/bcmd.1997.0155

Cancer Therapy Evaluation Program. Common toxicity criteria. Bethesda, Md.: National Cancer Institute, March 1998.

Druker BJ, 1994, J Biol Chem, 269, 5387, 10.1016/S0021-9258(17)37699-8

Oda T, 1994, J Biol Chem, 269, 22925, 10.1016/S0021-9258(17)31596-X

Nichols GL, 1994, Blood, 84, 2912, 10.1182/blood.V84.9.2912.2912

ten Hoeve J, 1994, Blood, 84, 1731, 10.1182/blood.V84.6.1731.1731

Heaney C, 1997, Blood, 89, 297, 10.1182/blood.V89.1.297

Senechal K, 1998, Mol Cell Biol, 18, 5082, 10.1128/MCB.18.9.5082

10.1056/NEJM200104053441402

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 344 Số 14

1031-1037

Thông tin tác giả